CN1384835A - 聚(adp－核糖)聚合酶的三环抑制剂 - Google Patents

聚(adp－核糖)聚合酶的三环抑制剂 Download PDF

Info

Publication number
CN1384835A
CN1384835A CN00815066A CN00815066A CN1384835A CN 1384835 A CN1384835 A CN 1384835A CN 00815066 A CN00815066 A CN 00815066A CN 00815066 A CN00815066 A CN 00815066A CN 1384835 A CN1384835 A CN 1384835A
Authority
CN
China
Prior art keywords
aryl
heteroaryl
alkynyl
alkenyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00815066A
Other languages
English (en)
Chinese (zh)
Inventor
S·E·韦伯
D·J·斯卡利茨基
J·G·蒂赫
R·A·库姆普夫
J·T·马拉科维茨
B·W·伊斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Agouron Pharmaceuticals LLC
Original Assignee
Cancer Research Campaign Technology Ltd
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd, Agouron Pharmaceuticals LLC filed Critical Cancer Research Campaign Technology Ltd
Publication of CN1384835A publication Critical patent/CN1384835A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN00815066A 1999-08-31 2000-08-31 聚(adp－核糖)聚合酶的三环抑制剂 Pending CN1384835A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
US60/152,142 1999-08-31

Publications (1)

Publication Number Publication Date
CN1384835A true CN1384835A (zh) 2002-12-11

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00815066A Pending CN1384835A (zh) 1999-08-31 2000-08-31 聚(adp－核糖)聚合酶的三环抑制剂

Country Status (48)

Country Link
US (1) US6548494B1 (enExample)
EP (1) EP1208104B1 (enExample)
JP (1) JP4272375B2 (enExample)
KR (1) KR20020038742A (enExample)
CN (1) CN1384835A (enExample)
AP (1) AP1553A (enExample)
AR (1) AR035162A1 (enExample)
AT (1) ATE287406T1 (enExample)
AU (1) AU781826B2 (enExample)
BG (1) BG106562A (enExample)
BR (1) BR0015051A (enExample)
CA (1) CA2382404C (enExample)
CO (1) CO5200769A1 (enExample)
CR (1) CR6577A (enExample)
CZ (1) CZ2002613A3 (enExample)
DE (1) DE60017575T2 (enExample)
DK (1) DK1208104T3 (enExample)
DO (1) DOP2000000069A (enExample)
DZ (1) DZ3216A1 (enExample)
EA (1) EA200200306A1 (enExample)
EC (1) ECSP003637A (enExample)
EE (1) EE200200100A (enExample)
ES (1) ES2234657T3 (enExample)
GE (1) GEP20043268B (enExample)
GT (1) GT200000145A (enExample)
HK (1) HK1045509B (enExample)
HR (1) HRP20020271A2 (enExample)
HU (1) HUP0202703A3 (enExample)
IL (1) IL147863A0 (enExample)
IS (1) IS6289A (enExample)
MA (1) MA25876A1 (enExample)
MX (1) MXPA02002138A (enExample)
MY (1) MY135910A (enExample)
NO (1) NO322475B1 (enExample)
NZ (1) NZ516793A (enExample)
OA (1) OA12016A (enExample)
PA (1) PA8501801A1 (enExample)
PE (1) PE20010538A1 (enExample)
PL (1) PL354242A1 (enExample)
PT (1) PT1208104E (enExample)
SI (1) SI1208104T1 (enExample)
SK (1) SK2592002A3 (enExample)
SV (1) SV2003000162A (enExample)
UA (1) UA73144C2 (enExample)
UY (1) UY26323A1 (enExample)
WO (1) WO2001016136A2 (enExample)
YU (1) YU15102A (enExample)
ZA (1) ZA200200830B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856313B (zh) * 2003-07-25 2011-01-12 癌症研究技术有限公司 治疗化合物
CN106458935A (zh) * 2014-01-05 2017-02-22 华盛顿大学 用于聚(adp‑核糖)聚合酶‑1(parp‑1)的放射性标记示踪物，其方法和用途
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
KR20010087401A (ko) * 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
MXPA06000993A (es) * 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
CA2595290C (en) * 2005-01-19 2013-06-25 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
US20090226412A1 (en) * 2005-06-24 2009-09-10 Ono Pharmaceutical Co., Ltd., Agent for reduction of bleeding in cerebrovascular disorder
EP1906948A4 (en) * 2005-07-18 2010-03-17 Bipar Sciences Inc TREATMENT OF CANCER
MX2008001152A (es) * 2005-08-05 2008-04-02 Astrazeneca Ab Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2655257A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009034326A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
AU2008321382A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2892344A1 (de) * 2012-09-05 2015-07-15 Bayer CropScience AG Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CN112351778B (zh) * 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
SG11202108399PA (en) * 2019-02-02 2021-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indolo heptamyl oxime analogue as parp inhibitor
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
JP2024503380A (ja) 2021-01-08 2024-01-25 サイブレクサ ２，インコーポレイテッド コンジュゲート連結部分を調製するための方法
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
CA3250650A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill ARYLBENZOISOXAZOLE COMPOUNDS USED AS IP6K AND IPMK INHIBITORS AND THEIR METHODS OF USE
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (enExample) 1964-03-24
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
AU674613B2 (en) 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
DK0841924T3 (da) * 1995-08-02 2003-02-10 Univ Newcastle Ventures Ltd Benzimidazolforbindelser
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
EP1009404A4 (en) 1997-05-13 2009-07-01 Octamer Inc PROCESS FOR TREATING INFLAMMATION OR INFLAMMATORY DISEASES USING POLY-ADP RIBOSE POLYMERASE INHIBITORS
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856313B (zh) * 2003-07-25 2011-01-12 癌症研究技术有限公司 治疗化合物
CN106458935A (zh) * 2014-01-05 2017-02-22 华盛顿大学 用于聚(adp‑核糖)聚合酶‑1(parp‑1)的放射性标记示踪物，其方法和用途
CN106458935B (zh) * 2014-01-05 2019-05-28 华盛顿大学 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂

Also Published As

Publication number Publication date
MXPA02002138A (es) 2003-08-20
DE60017575D1 (de) 2005-02-24
SK2592002A3 (en) 2002-10-08
UA73144C2 (en) 2005-06-15
NO20020421D0 (no) 2002-01-28
BR0015051A (pt) 2002-06-25
EP1208104A2 (en) 2002-05-29
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
CA2382404A1 (en) 2001-03-08
AP1553A (en) 2006-01-18
ATE287406T1 (de) 2005-02-15
PE20010538A1 (es) 2001-05-22
WO2001016136A3 (en) 2001-06-21
ES2234657T3 (es) 2005-07-01
CR6577A (es) 2003-12-05
GT200000145A (es) 2002-02-21
DE60017575T2 (de) 2005-06-09
IL147863A0 (en) 2002-08-14
CZ2002613A3 (cs) 2002-08-14
GEP20043268B (en) 2004-06-25
CO5200769A1 (es) 2002-09-27
DOP2000000069A (es) 2002-08-30
NZ516793A (en) 2004-03-26
EA200200306A1 (ru) 2002-08-29
MA25876A1 (fr) 2003-10-01
BG106562A (bg) 2003-03-31
AU781826B2 (en) 2005-06-16
AR035162A1 (es) 2004-05-05
HUP0202703A3 (en) 2004-12-28
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
AU7338900A (en) 2001-03-26
HUP0202703A2 (hu) 2002-12-28
HRP20020271A2 (en) 2005-12-31
EE200200100A (et) 2003-06-16
EP1208104B1 (en) 2005-01-19
IS6289A (is) 2002-02-27
SI1208104T1 (en) 2005-06-30
DZ3216A1 (fr) 2001-03-08
NO20020421L (no) 2002-04-25
HK1045509A1 (en) 2002-11-29
JP2003513015A (ja) 2003-04-08
ZA200200830B (en) 2003-03-26
DK1208104T3 (da) 2005-05-02
HK1045509B (en) 2005-04-29
PA8501801A1 (es) 2002-08-26
MY135910A (en) 2008-07-31
ECSP003637A (es) 2002-03-25
CA2382404C (en) 2009-03-24
NO322475B1 (no) 2006-10-09
YU15102A (sh) 2004-12-31
KR20020038742A (ko) 2002-05-23
PT1208104E (pt) 2005-04-29
UY26323A1 (es) 2001-04-30
JP4272375B2 (ja) 2009-06-03
WO2001016136B1 (en) 2001-11-15
PL354242A1 (en) 2003-12-29

Similar Documents

Publication Publication Date Title
US6548494B1 (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
CN1289501C (zh) 三环稠合杂环化合物、其制备方法以及包含该化合物的药物
US10077243B2 (en) Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN1823068A (zh) 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
CN1273469C (zh) 作为保胎用催产素受体拮抗剂的三环二氮杂䓬
HK1052508A1 (zh) 作为凝血因子xa抑制剂的含氮杂双环
CN1342161A (zh) 聚(adp－核糖)聚合酶的三环抑制剂
CN1294133C (zh) 作为gaba受体配体的咪唑并－嘧啶衍生物
CN1684964A (zh) 一些新的咪唑并吡啶及其用途
CN1278819A (zh) 作为促肾上腺皮质素释放激素拮抗剂、可用于治疗cns障碍和紧张相关性疾病的杂环基取代的环稠合吡啶和嘧啶
CN1511157A (zh) 作为药物的新的吡咯衍生物
CN1694886A (zh) 作为周期素依赖性激酶抑制剂的咪唑并吡嗪
CN1499972A (zh) 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物
CN1880317A (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
EP4221703A1 (en) Hsd17b13 inhibitors and uses thereof
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1893944A (zh) 具有抗增殖活性的3－氰基喹啉衍生物
CN1501931A (zh) 新颖的三环羟基羧酰胺及其衍生物保胎用催产素受体拮抗剂
CN1225637A (zh) 吡咯并三嗪和嘧啶化合物
HK1052340A (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2023141866A1 (en) Pyrazolopyrimidines as modulators of spermine oxidase
CN1829720A (zh) 7－取代的3－硝基－吡唑并[1,5－a]嘧啶类
HK1113483A (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
HK1068133A (en) Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1052340

Country of ref document: HK